Bortezomib With Melphalan and Prednisone for Multiple Myeloma: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Bortezomib With Melphalan and Prednisone for Multiple Myeloma (NCT00734149), a na phase 2 study. The primary outcome is Response.

2. Clinical Question

3. Trial Design

The registry record describes a phase 2 prospective study of bortezomib combined with melphalan and prednisone in patients with previously untreated multiple myeloma. It is listed as completed, with a single-group model, no masking, and allocation recorded as NA. Enrollment is listed as 45. The study dates are recorded as 2004-07 for start and 2008-02 for primary completion.

A single-group design describes outcomes among participants receiving the combination; it does not create a concurrent control group. The study summary mentions comparison with an historical control group as an aim, but no historical-control results, methods for selecting that control, or adjusted comparison are reported in the registry record. The record therefore does not support interpreting the listed outcomes as a randomized or like-for-like comparison.

The intervention is the three-drug combination. The arm description specifies intravenous bortezomib at 1.3 mg/m2 as a 3-5 second bolus on days 1, 4, 8, and 11 of a 28 day cycle, with six cycles planned. It also states that when melphalan and bortezomib are given on the same day, melphalan is given at least one hour before bortezomib. The remaining melphalan schedule text is truncated, so its full instructions are not reported in the registry record. The provided arm description does not give a complete prednisone schedule.

The listed outcomes include response, adverse events, and median duration of response. The primary response endpoint is framed as a participant count and has a stated assessment time after treatment completion. Although the registry lists three outcome measures, only two secondary outcome titles are included in the record. The number of analyses is recorded as zero; this does not supply an analysis plan or explain how results were handled. Specific protocol details, including a sample-size justification and analysis methods, are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Response, measured over 6 weeks following completion of treatment.

The primary endpoint is titled Response and is expressed as a number of participants. The registry definition describes overall response as complete response plus partial response according to Southwest Oncology Group Criteria, assessed 6 weeks following completion of treatment. It requires measurable, quantifiable protein criteria, including quantitative immunoglobulin and/or urine M-component; if both are present, quantitative immunoglobulin is to be followed for response.

Complete remission is described in terms of absence of bone marrow or blood findings of multiple myeloma and disappearance of serum and urine M-components on electrophoresis or immunofixation, with no evidence of increasing anemia. Partial remission is defined using reductions in quantitative immunoglobulin and, when present, urine M-component. The registry also describes stable/no remission using a reduction threshold, but the wording contains apparent transcription errors. The criteria should therefore be read as the registry states them, not as a substitute for a complete protocol definition.

Response is used as an indicator of tumor response under the specified criteria. It is a categorized outcome, rather than a direct measure of how long response lasts or of survival. The registry lists median duration of response separately as a secondary outcome. The actual primary response count or rate is not reported in the registry record, so the endpoint definition alone cannot establish what response was observed.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

For a binary endpoint such as response, the basic outcome is whether each participant meets the stated response definition. A count records how many participants meet that definition; a rate expresses that count relative to an analyzed group. The registry identifies the primary outcome as a participant count, but does not report the observed response count, a rate, or an uncertainty interval. No response estimate should be inferred from the enrollment figure or from the endpoint description.

What does a single-group result tell us?

In a single-group study, the observed outcomes describe the participants who received the study regimen. There is no concurrent randomized group to provide a direct estimate of what would have happened under another intervention. Historical comparisons can sometimes be used descriptively, but their interpretation depends on how the earlier group was selected and whether its patients, outcome definitions, follow-up, and other relevant features are comparable. The registry summary mentions a historical-control aim, but comparator details and comparative results are not reported in the registry record.

Random allocation is one way to reduce systematic differences between groups at the start of a study. Here, the model is listed as single-group and allocation as NA. Therefore, any contrast with an external or historical experience would not have the same protection against confounding as a randomized comparison. The registry record does not report an adjustment strategy or methods for handling differences from a historical control.

How should uncertainty be understood?

A confidence interval is a range of values compatible with the observed data under a specified statistical model. It communicates precision as well as the direction and scale of an estimate. A narrow interval generally indicates more precision than a wide interval, while neither an interval nor a point estimate alone resolves limitations in study design. No confidence interval for the primary response outcome is reported in the registry record, so its statistical precision cannot be evaluated.

A p-value, when used, describes how unusual data at least as inconsistent with a specified null hypothesis would be under the assumptions of that test. It does not measure the probability that a treatment works, and it does not establish clinical importance. The registry records zero analyses and does not report a primary endpoint p-value or an inferential analysis plan. No statistical significance conclusion can be drawn from the absent result.

What do the planning illustrations mean?

Sample-size calculations are planning tools. They describe how many participants might be required under stated assumptions about the target effect, significance level, allocation, and statistical approximation. They are not observed outcomes and should not be interpreted as evidence that a study had a particular probability of detecting its actual effect. The planning assumptions described for this record use a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation, with the target effect expressed as a fraction of the observed effect. Those are illustration assumptions, not a reported design justification for this single-group trial.

Because the registry entries do not include a numerical primary effect or calculated planning values, the illustrations cannot be used to recover the response result or establish the trial's precision. A sample-size justification for the actual study is not reported in the registry record. The record also does not report whether interim analyses were planned or conducted.

Why does the endpoint definition matter?

Outcome definitions determine what is counted as an event. This response endpoint combines complete and partial response, while the registry's detailed criteria distinguish those categories and specify measurable protein evidence. Such rules support consistent classification when applied as written. However, transcription irregularities in the registry definition and absent results make it difficult to assess exactly how the criteria were applied. A protocol or analysis report that resolves those details is not reported in the registry record.

Finally, outcome summaries and analysis populations answer different questions. Enrollment describes the study's listed size; an analyzed population would identify who contributed to a particular endpoint and under what rules. The registry does not report the response analysis population or missing-data approach. As a result, the relation between enrollment, endpoint assessment, and any analyzed response result cannot be evaluated.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("Bortezomib+Melphalan+Prednisone")
n      <- c(44)
events <- c(42)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  Bortezomib+Melphalan+Prednisone  44  42  95.5  84.5  99.4  84.9  98.7  84.9  98.6

11. Multiplicity, Missing Data and Analysis Populations

The registry lists Response as the primary outcome and includes Number of Patients With Any Grade or Severe Adverse Event and Median Duration of Response among the secondary outcome titles. It also records three outcome measures, while only two secondary outcome titles are listed. This information does not describe a prespecified hierarchy of hypotheses or a multiplicity adjustment. Such methods are not reported in the registry record.

Multiplicity arises when several outcomes or analyses are examined: the more opportunities there are to identify an apparently notable result, the more important it is to understand which analyses were planned and how interpretation was controlled. This is a general statistical consideration, not a claim that a particular adjustment was used in this study. The record provides no analysis-level results and records zero analyses, so it is not possible to determine which comparisons, if any, were performed or how secondary outcomes were interpreted.

The registry does not report the number of participants assessed for the primary endpoint, the response analysis population, or how missing assessments were handled. It is also silent on exclusions from analysis, the timing and completeness of follow-up, and any sensitivity analyses. These details matter because a participant without an assessable response may be handled differently across analysis approaches, changing the interpretation of a response summary.

For duration of response, the record gives the outcome title but no result, analysis population, or details of how duration was defined or analyzed. The same lack of analysis information prevents assessment of censoring or incomplete follow-up. These items are not reported in the registry record; they should not be filled in by assumptions about common practice.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 1% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: neuropathy: sensory (4.4%), death not associated with ctcae term - disease progression nos (4.4%), ileus, gi (functional obstruction of bowel, i.e., neuroconstipation) (2.2%), infection with unknown anc - lung (pneumonia) (2.2%), seizure (2.2%).

The adverse-event summary lists 45 at risk in the serious-event category and 6 affected, and 45 at risk in the other-event category and 30 affected. These are descriptive counts within the single study group, not a comparison with another treatment. The record does not explain whether participants could be counted in both categories, how the categories were operationalized, or whether the figures represent all events or people with at least one event. Interpret the categories according to their registry labels rather than as a complete accounting of safety.

Listed serious-event terms and percentages include Neuropathy: sensory at 4.4%, Death Not Associated with CTCAE term - Disease Progression NOS at 4.4%, Ileus, GI (functional obstruction of bowel, i.e., neuroconstipation) at 2.2%, Infection with unknown ANC - Lung (pneumonia) at 2.2%, Seizure at 2.2%, and Secondary Malignancy - possibly related to cancer treatment at 2.2%. The record does not provide term-specific counts alongside these percentages or a complete list of adverse events.

A serious adverse event is a category of safety reporting, not a finding that the study regimen caused the event. The registry record does not report causal attribution for these listed terms, except for wording included in the term labels, and does not provide a comparative risk estimate. The listed adverse-event information should therefore be read as a limited descriptive summary, not as a complete safety profile.

13. What the Result Does, and Does Not, Mean

The registry record establishes that a phase 2, prospective, single-group study evaluated a bortezomib, melphalan, and prednisone combination in patients with previously untreated multiple myeloma. It specifies a response endpoint based on complete or partial response criteria and gives a follow-up time for that assessment. The record also contains selected adverse-event counts and term percentages. These details describe the study's focus and some reported safety information.

The primary response outcome itself is not reported in the registry record. There is no response count or rate, no confidence interval, and no primary analysis result. The record therefore does not show the magnitude or precision of response in the study group. A stated endpoint and a planned regimen are not substitutes for outcome data.

The design does not provide a concurrent comparator. The summary's reference to an historical control does not supply historical-control data or a comparison method. Thus, the record cannot establish a relative treatment effect or support a causal conclusion about the combination. Descriptive outcomes from a single group can be informative about what was recorded in that group, but they do not isolate the effect of treatment from other explanations.

Likewise, the adverse-event summary does not determine whether an event was caused by treatment, and it is not a comparison of safety between interventions. The listed median duration of response outcome has no result in the record. Missing information about analysis populations, outcome completeness, and statistical methods further limits assessment.

These limitations do not show that the regimen was ineffective or unsafe. They identify what the available registry record can and cannot establish. The appropriate reading is that key result information needed to quantify the primary response outcome and evaluate comparative effects is not reported in the registry record.

14. Why This Trial Matters Statistically

This study is statistically notable for the distinction between a stated comparative aim and a recorded single-group design. The summary says the purpose included comparison with an historical control, while the registry lists a single-group model and allocation NA. That distinction matters because a treatment contrast requires information about both the treated group and the comparison group, along with a defensible basis for comparing them. The record does not report those comparative results or methods.

The endpoint definition also illustrates why outcome rules need to be clear. Overall response combines complete and partial response, while the registry separately describes criteria for each category and specifies protein measurements used in assessment. Such detail can make a clinical endpoint more reproducible, but transcription problems in the record and the absence of endpoint results constrain evaluation of its application.

Finally, a registry entry can include enrollment, an endpoint definition, and safety summaries without reporting the principal efficacy result or its uncertainty. Those pieces of information serve different statistical purposes: enrollment describes the study record, endpoint rules define what would count, and outcome estimates summarize what was observed. They cannot stand in for one another. Here, the missing primary result prevents readers from assessing both the observed response and its precision, while the lack of a concurrent control limits causal interpretation.

These features make transparent reporting particularly important. Clear primary results, analysis populations, missing-data handling, and comparator methods would be needed to judge how complete and interpretable the evidence is. Those details are not reported in the registry record.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several limitations specific to this record affect interpretation. The primary response result is not reported, despite a detailed endpoint definition and a stated assessment time. There is no response count, response rate, confidence interval, or inferential result, so neither the observed magnitude nor its precision can be assessed.

The study is recorded as single-group, with allocation NA and no masking. The summary mentions a historical-control comparison, but the registry does not report a comparator group, historical-control outcome data, selection criteria, or methods for accounting for differences between groups. The record therefore does not support a like-for-like treatment comparison.

The arm description is incomplete: the melphalan schedule ends mid-text, and a complete prednisone schedule is not reported in the record. The primary endpoint definition also contains apparent transcription errors. These gaps limit assessment of the full intervention and precise operationalization of response.

For safety, the registry reports affected and at-risk counts and selected serious-event terms, but does not provide a complete event listing or clarify all counting conventions. It does not establish causal attribution for the listed events. The secondary duration-of-response outcome has no reported result or analysis details.

The analysis population, missing-data methods, sample-size justification, interim-analysis plans, multiplicity approach, and detailed statistical plan are not reported in the registry record. Their absence limits assessment of completeness, precision, and robustness; none should be inferred from standard practice.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Bortezomib With Melphalan and Prednisone for Multiple Myeloma — NCT00734149.
• Registry record last updated 2023-11-07; status last verified 2016-03.
• Results first posted 2013-05-31.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

The registry record describes a completed phase 2 prospective study of bortezomib with melphalan and prednisone for previously untreated multiple myeloma. It lists a single-group model, allocation NA, no masking, and enrollment of 45. The primary outcome is response, defined as complete or partial response under Southwest Oncology Group Criteria, assessed 6 weeks following completion of treatment.

The registry lists adverse events and median duration of response as secondary outcomes. It reports adverse-event counts and selected serious-event terms, but the primary response result and duration-of-response result are not reported in the registry record. A historical-control comparison is mentioned as an aim, but comparator details and comparative results are not recorded. The analysis population, missing-data methods, and detailed statistical plan are also not reported.